Back to Search Start Over

Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature

Authors :
Serena Vita
Silvia Rosati
Tommaso Ascoli Bartoli
Alessia Beccacece
Alessandra D’Abramo
Andrea Mariano
Laura Scorzolini
Delia Goletti
Emanuele Nicastri
Source :
Pathogens, Vol 11, Iss 8, p 882 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful microorganisms, including viruses such as Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2). The US Food and Drug Administration (FDA) and the European Medical Agency (EMA) have already authorized monoclonal antibodies of anti-SARS-CoV-2 to treat mild to moderate CoronaVIrus Disease-2019 (COVID-19) in patients at risk of developing severe disease. More recently, monoclonal antibodies anti-SARS-CoV-2 have been authorized for primary and secondary prophylaxis in patients at high risk of severe disease for background comorbidity. Primary or pre-exposure prophylaxis prevents COVID-19 in unexposed people, whereas secondary or postexposure prophylaxis prevent COVID-19 in recently exposed people to individuals with laboratory-confirmed SARS-CoV-2. This review focuses briefly on therapeutic indications of currently available monoclonal antibodies for COVID-19 pre- and postexposure prophylaxis and on the efficacy of convalescent plasma.

Details

Language :
English
ISSN :
20760817
Volume :
11
Issue :
8
Database :
Directory of Open Access Journals
Journal :
Pathogens
Publication Type :
Academic Journal
Accession number :
edsdoj.2ea6b6a6e6a94e1bbdca1bcc74412716
Document Type :
article
Full Text :
https://doi.org/10.3390/pathogens11080882